# Wockhardt gets USFDA nod for novel drug Zaynich 2026-08-09T21:01:26+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 1 independent outlet Wockhardt has received US Food and Drug Administration approval for Zaynich, a novel drug discovered and developed in-house, marking a first for an Indian pharmaceutical company. The company spent nearly Rs 6,800 crore and over two decades on the drug’s development. Zaynich is expected to drive Wockhardt’s next phase of growth after it returned to profitability in FY26. The approval comes as India Inc reports stronger profit margins but moderate revenue growth, with business confidence hitting a record low in the June quarter, according to the BT-C Fore Business Confidence Index. The survey cited global uncertainties and domestic headwinds as factors weighing on sentiment. ## Coverage - businesstoday.in Tags: business confidence, India Inc, pharmaceuticals, USFDA approval, Wockhardt, Zaynich Canonical: https://indianopinion.org/wockhardt-gets-usfda-nod-for-novel-drug-zaynich/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/wockhardt-gets-usfda-nod-for-novel-drug-zaynich/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes.